Hugo Fry, Topas Therapeutics CEO
May 5, 2025 03:01 AM EDTUpdated 06:18 AM
R&D

Ex­clu­sive: Topas claims suc­cess in ear­ly test of 'im­mune tol­er­ance' ther­a­py for celi­ac dis­ease

Ryan Cross

Senior Science Correspondent

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Ab­b­Vie inks $700M deal with IGI for mul­ti­ple myelo­ma trispe­cif­ic an­ti­body

Kid­ney health biotech emerges with $54M to fol­low in Ver­tex’s foot­steps

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times